View Post This content is machine translated Invitation to the 12th IBD Roadshow | June 23-25, 2025 | with Professor Bruce Sands Acceleration in IBD Treatment: How early and holistic care leads to better outcomes We cordially invite you to the 12th IBD Roadshow from June 23-25, 2025! The internationally renowned expert Professor Bruce Sands (Icahn School of Medicine, Mount Sinai, New York, USA) is touring Switzerland. During six events – in St. Gallen, Basel, Bern, Lucerne, Lausanne and Geneva – you will have the opportunity to learn about the latest findings on IBD therapy at first hand…. Dieser Inhalt ist nur für Benutzer der Gruppe: Medizinische Fachperson zugänglich Jetzt beitretenAlready a member? Log in here View Post
View Post This content is machine translated Sponsored Content: UEGW update: Post-hoc analyses of the SEQUENCE study Risankizumab is convincing compared to ustekinumab [1] The SEQUENCE comparative study recently published in the New England Journal of Medicine (NEJM) compared the two interleukin (IL)-23 and IL-12/-23 inhibitors risankizumab (SKYRIZI®) and ustekinumab in Crohn’s disease (CD) patients [1-3]. Supplementary post-hoc analyses have now been presented at this year’s United European Gastroenterology Week (UEGW) from October 12 to 15, 2024 in Vienna [4-6]. The results show, among other things, that risankizumab achieves numerically higher efficacy rates compared to ustekinumab regardless of disease duration, leads to greater normalization of biomarkers and significantly improves quality of life [4-6]. View Post
View Post This content is machine translated Sponsored Content: Crohn's disease Biomarkers underline superiority of risankizumab compared to ustekinumab in Crohn’s disease [1] In the SEQUENCE study, risankizumab was compared with ustekinumab for the treatment of Crohn’s disease (CD) in patients who had failed anti-TNF therapies. Biomarkers such as fecal calprotectin (FC) and C-reactive protein (CRP) were also measured [1]. In addition to the clinical and endoscopic endpoints, these biomarkers made it possible to objectively assess the course of the disease [1]. View Post
View Post This content is machine translated Sponsored Content: United European Gastroenterology Week (UEGW) 2023 Risankizumab demonstrates superiority compared to ustekinumab in Crohn’s disease [1] Data from the current SEQUENCE study was presented at the United European Gastroenterology Week (UEGW), which took place from October 14 to 17, 2023, and has since been published [1,2]. In der randomisierten Phase-III-Head-to-Head-Studie wurde Risankizumab (SKYRIZI®) mit Ustekinumab zur Behandlung erwachsener Patient:innen mit mittelschwerem bis schwerem aktivem Morbus Crohn (CD, Crohn’s Disease) verglichen, bei denen eine oder mehrere Anti-TNF-Therapien versagt hatten [1]. Risankizumab achieved all primary and secondary endpoints compared to ustekinumab and demonstrated superiority [1]. SEQUENCE is therefore the only head-to-head study in Crohn’s disease to show superiority of a biologic over another biologic. View Post
View Post This content is machine translated 11th Swiss IBD Roadshow “Curing mucosa is our major goal” The meanwhile 11th Swiss IBD Roadshow (10. – 12. June 2024) took place this year under the title “ADVANCED THERAPIES IN IBD – TOWARDS A NEW SEQUENCE”. Between his lectures in seven Swiss centers, Prof. Laurent Peyrin-Biroulet from Nancy University Hospital, France, shared his experiences and thoughts on advanced therapies and treatment procedures in inflammatory bowel disease (IBD). He highlighted the effectiveness of recent additions to the treatment landscape and called for a closer analysis of the risk-benefit profile of available therapies. View Post
